United States

Veraxa Biotech AG - Post de-SPAC (VRXA)

Track

Track

Veraxa Biotech AG recorded two insider transactions on August 27, 2026, involving total purchases of 82,650 USD. Chief Executive Officer Christoph Rudiger Antz and Oliver Rolf Baumann acquired shares following a 90-day period where the stock price declined by 86.2 percent. No recent Geschäftsergebnis or official financial disclosures accompanied these acquisitions.
Ticker: VRXA
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Baumann Oliver Rolf Non-Executive Director
Transaction date
Purchase
Price
273.94
Quantity 68,975 -41.9%
Value US$363,255
Antz Christoph Rudiger Chief Executive Officer Executive Director
Transaction date
Purchase
Price
77.29
Quantity 87,318 -17.6%
Value US$540,155
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-31 2026-08-27 B Purchase
Baumann Oliver Rolf
Non-Executive Director
68,975 -41.9%
273.94
US$363,255 		68,975 -41.9% 273.94 US$363,255
2026-08-31 2026-08-27 B Purchase
Antz Christoph Rudiger

Chief Executive Officer

Executive Director
87,318 -17.6%
77.29
US$540,155 		87,318 -17.6% 77.29 US$540,155
Explore more

More insider trading research around Veraxa Biotech AG - Post de-SPAC

More insider trades in United States
Insider trading in North America